Stockreport

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer [...

Guardant Health, Inc.  (GH) 
Last guardant health, inc. earnings: 2/24 04:03 pm Check Earnings Report
PDF Approval supported by data from Pfizer's BREAKWATER trial demonstrating improved outcomes in BRAF V600E-mutant mCRC with encorafenib-based treatment PALO ALTO, Calif. [Read more]